These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 29452901)

  • 1. Improved cost-effectiveness of short-course radiotherapy in elderly and/or frail patients with glioblastoma.
    Ghosh S; Baker S; de Castro DG; Kepka L; Kumar N; Sinaika V; Matiello J; Lomidze D; Dyttus-Cebulok K; Rosenblatt E; Fidarova E; Roa W
    Radiother Oncol; 2018 Apr; 127(1):114-120. PubMed ID: 29452901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
    Lamers LM; Stupp R; van den Bent MJ; Al MJ; Gorlia T; Wasserfallen JB; Mittmann N; Jin Seung S; Crott R; Uyl-de Groot CA;
    Cancer; 2008 Mar; 112(6):1337-44. PubMed ID: 18213621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme.
    Roa W; Kepka L; Kumar N; Sinaika V; Matiello J; Lomidze D; Hentati D; Guedes de Castro D; Dyttus-Cebulok K; Drodge S; Ghosh S; Jeremić B; Rosenblatt E; Fidarova E
    J Clin Oncol; 2015 Dec; 33(35):4145-50. PubMed ID: 26392096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival Outcomes With Short-Course Radiation Therapy in Elderly Patients With Glioblastoma: Data From a Randomized Phase 3 Trial.
    Guedes de Castro D; Matiello J; Roa W; Ghosh S; Kepka L; Kumar N; Sinaika V; Lomidze D; Hentati D; Rosenblatt E; Fidarova E
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):931-938. PubMed ID: 28602417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Carbon Ion Radiation Therapy for Skull Base Chordoma Utilizing Long-Term (10-Year) Outcome Data.
    Sprave T; Verma V; Sterzing F; Bruckner T; Hees K; Land B; Jäkel O; Herfarth K; Debus J; Uhl M
    Anticancer Res; 2018 Aug; 38(8):4853-4858. PubMed ID: 30061259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
    Waschke A; Arefian H; Walter J; Hartmann M; Maschmann J; Kalff R
    J Neurooncol; 2018 Jun; 138(2):359-367. PubMed ID: 29468446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study.
    Jeremic B; Shibamoto Y; Grujicic D; Milicic B; Stojanovic M; Nikolic N; Dagovic A; Aleksandrovic J
    J Neurooncol; 1999 Aug; 44(1):85-90. PubMed ID: 10582674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
    Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
    J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme.
    Roa W; Xing JZ; Small C; Kortmann R; Miriamanoff R; Okunieff P; Shibamoto Y; Jeremic B
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1643-50. PubMed ID: 19895247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model.
    Connock M; Auguste P; Dussart C; Guyotat J; Armoiry X
    J Neurooncol; 2019 Jul; 143(3):605-611. PubMed ID: 31127507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
    Messali A; Villacorta R; Hay JW
    Pharmacoeconomics; 2014 Dec; 32(12):1201-12. PubMed ID: 25085219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
    van den Hout WB; Kramer GW; Noordijk EM; Leer JW
    J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
    Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
    J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
    Uyl-de Groot CA; Stupp R; van der Bent M
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):235-41. PubMed ID: 19527095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
    Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
    J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.
    Nieder C; Nestle U; Ketter R; Kolles H; Gentner SJ; Steudel WI; Schnabel K
    Radiat Oncol Investig; 1999; 7(1):36-41. PubMed ID: 10030622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
    Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.